Rittmeyer et al. [25] reported that atezolizumab provides survival benefits in previously treated NSCLC patients in accordance with the 1% cutoff value, and this improvement was associated with PD-L1 expression in tumor cells, as assessed via the SP142 PD-L1 immunostaining assay. This evidence concerns the gene CD274 and non-small cell lung carcinoma.